Nebivolol and the Endothelin (ET)-1 System

NCT01395329 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2019-01-02

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor tone in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo.

Conditions

Interventions

DRUG

Nebivolol

5 mg tablet to be taken by mouth once per day for 12 weeks

DRUG

Metoprolol

100 mg tablet to be taken by mouth once per day for 12 weeks

DRUG

Placebo

gelatin capsule to be taken by mouth once per day for 12 weeks

OTHER

Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)

The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.

OTHER

FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)

The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.

OTHER

FBF response to Acetylcholine

The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.

OTHER

FBF response to Sodium Nitroprusside

The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.

OTHER

FBF response to BQ-123+BQ-788+ACh

The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY
  • University of Colorado, Boulder

    lead OTHER

Principal Investigators

  • Christopher A DeSouza, Ph.D. · University of Colorado at Boulder

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2016-11-30
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01395329 on ClinicalTrials.gov